A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Clinical trial NCT06083922 · RECRUITING
Trial details
- NCT number
- NCT06083922
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-16
- Primary completion
- 2026-10-01
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.